Moleculin Biotech Files 8-K Report

Ticker: MBRX · Form: 8-K · Filed: Apr 17, 2025 · CIK: 1659617

Moleculin Biotech, Inc. 8-K Filing Summary
FieldDetail
CompanyMoleculin Biotech, Inc. (MBRX)
Form Type8-K
Filed DateApr 17, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-statements, exhibits, disclosure

Related Tickers: MBRX

TL;DR

Moleculin Biotech filed an 8-K with financial statements and exhibits on April 17, 2025.

AI Summary

On April 17, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure related to the company's financial status and operations. No specific material events or transactions were detailed in the provided excerpt.

Why It Matters

This filing serves as a public record of Moleculin Biotech's financial statements and exhibits, providing transparency to investors and stakeholders regarding the company's financial health.

Risk Assessment

Risk Level: low — The filing appears to be a standard disclosure of financial statements and exhibits, not indicating any immediate significant risks or changes.

Key Players & Entities

  • Moleculin Biotech, Inc. (company) — Registrant
  • April 17, 2025 (date) — Date of earliest event reported
  • 5300 Memorial Drive, Suite 950, Houston, TX 77007 (address) — Principal executive offices
  • 713-300-5160 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing for Moleculin Biotech, Inc.?

The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the filing's content and item information.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on April 17, 2025.

What is Moleculin Biotech, Inc.'s principal executive office address?

Moleculin Biotech, Inc.'s principal executive office is located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.

What is the telephone number for Moleculin Biotech, Inc.?

The telephone number for Moleculin Biotech, Inc. is (713) 300-5160.

Under which section of the Securities Exchange Act is this 8-K filed?

This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2025 regarding Moleculin Biotech, Inc. (MBRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.